ClinVar and Clinical Variant Interpretation Resources

  • ClinVar is a publicly accessible database maintained by the National Center for Biotechnology Information (NCBI) that collects and presents information about the relationships between human genetic variants and clinical conditions. It is one of the most important resources in clinical genomics because it brings together variant interpretations submitted by clinical laboratories, research groups, expert panels, and other organizations. ClinVar helps researchers and healthcare professionals investigate whether a genetic variant has been associated with a disease, whether it is considered pathogenic or benign, and what evidence supports the reported interpretation. It is particularly important in the analysis of rare genetic disorders, inherited diseases, cancer predisposition, and pharmacogenomics.
  • Clinical variant interpretation is the process of evaluating whether a genetic change contributes to a particular disease, influences disease risk, affects treatment response, or has no established clinical significance. A variant may be detected through whole-genome sequencing, whole-exome sequencing, targeted gene panels, or other molecular diagnostic methods. However, identifying a variant does not automatically establish its clinical importance. Interpretation requires consideration of the variant’s molecular effect, population frequency, inheritance pattern, clinical presentation, functional evidence, segregation within families, previous reports, and the strength and quality of available evidence.
  • ClinVar stores information about genetic variants and their reported clinical significance, including single-nucleotide variants, small insertions and deletions, and selected larger genomic changes. Each record may include the variant description, associated condition, gene, clinical significance classification, review status, submitter information, supporting evidence, and links to other biological databases. Variants may be represented using genomic coordinates, reference and alternate alleles, HGVS descriptions, and identifiers such as dbSNP RefSNP IDs. Accurate interpretation requires attention to the genome assembly, transcript reference, and sequence nomenclature because the same variant can have different coordinate descriptions across assemblies or transcripts.
  • ClinVar distinguishes between a variant and a clinical assertion about that variant. A variant can have multiple interpretations because different laboratories or research groups may evaluate it using different evidence, patient populations, analytical methods, or classification procedures. These submissions are represented as clinical assertions and may differ in their conclusions. For example, one submitter may classify a variant as pathogenic while another may classify it as uncertain significance. ClinVar makes these differences visible rather than automatically treating every submission as a single definitive conclusion. Users should therefore examine the evidence, date, submitter, review status, and any expert-panel assessment associated with a record.
  • Clinical significance is commonly expressed using five major categories: benign, likely benign, uncertain significance, likely pathogenic, and pathogenic. Benign variants are considered not to cause the disease or condition under evaluation, while likely benign variants have evidence supporting a non-disease-causing interpretation. Variants of uncertain significance (VUS) have insufficient or conflicting evidence to establish whether they are benign or pathogenic. Likely pathogenic variants have substantial evidence supporting a disease-causing role, while pathogenic variants meet the applicable evidence requirements for a disease-causing classification. These classifications are generally condition-specific: a variant may be relevant to one clinical condition but not necessarily to another.
  • ClinVar uses review status indicators to communicate the level of review supporting a clinical assertion. These are often represented by a star system. A submission without assertion criteria may receive no review stars, while a single submitter providing criteria-based evidence may receive one star. Multiple submitters with criteria-based interpretations that agree may receive two stars. Three stars indicate review by an expert panel, and four stars indicate a practice guideline. The number of stars is not a direct measure of the biological certainty of a variant, but it helps users understand the degree of review and consensus behind the classification. Expert-panel and guideline-level interpretations generally provide stronger standardized oversight than an isolated submission.
  • An important principle in ClinVar is the distinction between a variant-level record and a condition-specific clinical interpretation. A single genetic variant may be associated with multiple diseases, phenotypes, inheritance patterns, or clinical contexts. Its significance may therefore differ depending on the condition being assessed. For example, a variant in a gene associated with several disorders may be pathogenic for one disease mechanism but benign or uncertain in another context. Clinical interpretation should always consider the specific gene–disease relationship, inheritance model, molecular mechanism, and phenotype rather than relying only on a variant’s general label.
  • The American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG/AMP) established widely used guidelines for classifying sequence variants associated with Mendelian disorders. These guidelines organize evidence into categories such as population data, computational and predictive data, functional studies, segregation evidence, de novo occurrence, allelic data, and other clinical observations. Evidence criteria are assigned different strengths, commonly described as very strong, strong, moderate, or supporting. Combinations of these criteria are used to reach a classification of pathogenic, likely pathogenic, uncertain significance, likely benign, or benign. Laboratories may also use disease-specific specifications developed by expert groups to refine the application of the general framework.
  • Population frequency is a major component of variant interpretation. Resources such as gnomAD provide allele frequencies across large population datasets and can help determine whether a variant is too common to plausibly cause a rare, highly penetrant disorder. However, population frequency alone does not establish whether a variant is benign or pathogenic. Interpretation must account for ancestry, population representation, disease prevalence, penetrance, inheritance, and the quality of the frequency data. Underrepresentation of some populations in reference datasets can make frequency-based interpretation less reliable for individuals from those populations.
  • ClinGen, the Clinical Genome Resource, complements ClinVar by providing expert-curated assessments of gene–disease validity, variant pathogenicity, and clinical actionability. Its expert panels develop disease- and gene-specific recommendations, including specifications for applying ACMG/AMP criteria. ClinGen also evaluates the strength of evidence linking particular genes to specific diseases. This distinction is important because a variant cannot be interpreted reliably without understanding whether the gene itself has a well-supported relationship with the disease under investigation. ClinGen resources can therefore help clarify the biological and clinical context behind a ClinVar assertion.
  • Other resources contribute complementary evidence to clinical variant interpretation. OMIM provides detailed information about human genes and inherited disorders, including known disease associations and phenotypic descriptions. Orphanet focuses on rare diseases and supports disease identification and classification. The Human Phenotype Ontology (HPO) provides standardized terms for describing clinical features, allowing patient phenotypes to be compared systematically with known disease profiles. These resources are useful for phenotype-driven analysis, particularly when a patient presents with a complex or rare clinical condition.
  • Population and disease-specific databases are also important. gnomAD provides population-level variation frequencies, while the 1000 Genomes Project and the International Genome Sample Resource provide reference variation data from diverse populations. The Database of Genomic Variants (DGV) catalogues structural variation observed in human populations, including many observations from individuals considered to be healthy. The Cancer Genome Atlas (TCGA), the Catalogue of Somatic Mutations in Cancer (COSMIC), and related cancer genomics resources provide information about somatic variants, cancer-associated genes, and tumour-specific molecular changes. These resources address different biological and clinical questions and should not be treated as interchangeable sources of evidence.
  • Clinical variant interpretation also depends on functional annotation. Tools and databases such as Ensembl Variant Effect Predictor (VEP), ANNOVAR, SnpEff, and related annotation systems help determine how variants may affect genes, transcripts, coding sequences, splice sites, and protein products. Predicted consequences include synonymous, missense, nonsense, frameshift, splice-site, intronic, and regulatory variants. Computational predictions can help prioritize variants, but they do not independently prove pathogenicity. Their reliability depends on transcript selection, annotation databases, prediction methods, and the biological context of the disease.
  • Phenotype-based interpretation is particularly valuable in rare disease diagnosis. A patient’s clinical features can be encoded using HPO terms and compared with disease-associated phenotypes in resources such as OMIM, Orphanet, and curated gene–disease databases. Tools including Exomiser and Phen2Gene can combine phenotype similarity with genetic evidence to prioritize candidate genes and variants. Such approaches can reduce the number of variants requiring detailed investigation, although phenotype similarity must be interpreted carefully because different disorders can share clinical features and some patients have incomplete or atypical presentations.
  • Variant interpretation also requires understanding inheritance and family data. A variant may be more relevant when it segregates with disease in affected relatives, appears de novo in a patient with a compatible disorder, or occurs in a homozygous or compound heterozygous state consistent with a recessive disease. Family-based analysis can help distinguish causal variants from incidental findings. However, incomplete penetrance, variable expressivity, phenocopies, mosaicism, and limitations in family sampling can complicate segregation analysis. A lack of observed segregation evidence does not automatically exclude a variant from clinical relevance.
  • Clinical laboratories frequently use standardized variant nomenclature and data exchange formats. The Human Genome Variation Society (HGVS) provides recommendations for describing sequence variants at genomic, coding-DNA, and protein levels. The Variant Call Format (VCF) is widely used to store detected variants from sequencing pipelines, while ClinVar records can be linked to identifiers and standardized descriptions. Consistent representation is essential for accurate database searches, comparison between laboratories, clinical reporting, and reproducibility. Variant normalization, reference genome selection, transcript choice, and left alignment of insertions and deletions can all affect whether two records are recognized as describing the same genetic change.
  • ClinVar supports searching, browsing, and programmatic retrieval of variant information. Users can search by gene symbol, variant identifier, genomic location, disease name, or clinical significance. NCBI provides access through its website, Entrez programming interfaces, and downloadable data files. These facilities allow bioinformatics pipelines to retrieve variant classifications and associated evidence for large-scale analyses. However, automated systems should not simply accept a database label without checking its review status, submission date, condition, conflicts, and supporting evidence. Clinical databases are updated as new evidence becomes available, so the date and version of retrieved information should be recorded.
  • A major challenge in clinical variant interpretation is the presence of conflicting classifications. Differences may arise from new scientific findings, distinct evidence thresholds, alternative disease definitions, differences in transcript selection, or incomplete access to patient-level evidence. A variant classified as uncertain significance may later be reclassified as benign or pathogenic when additional population, functional, segregation, or clinical evidence becomes available. For this reason, variant interpretation is not a one-time process. Periodic reanalysis and reclassification are important, particularly for patients whose initial genetic testing did not provide a definitive diagnosis.
  • Another challenge is the interpretation of variants of uncertain significance. A VUS should not generally be treated as a confirmed disease-causing variant or used alone to make major clinical decisions. Additional evidence may come from functional studies, family testing, improved phenotype characterization, population databases, or new clinical observations. The appropriate interpretation also depends on the disease, inheritance pattern, and clinical context. Communication of uncertainty is therefore an essential part of responsible genomic medicine.
  • Clinical variant interpretation must also consider ethical, legal, and privacy issues. Genetic information can reveal details about an individual’s health, biological relatives, ancestry, and future disease risks. Human genomic data may therefore require controlled access, informed consent, secure storage, and careful data-sharing procedures. Resources such as the European Genome-phenome Archive (EGA) and the NIH database of Genotypes and Phenotypes (dbGaP) provide controlled-access frameworks for many human genomic datasets. Public variant interpretations and controlled-access patient-level data serve different purposes and must be handled according to applicable consent and governance requirements.
  • In bioinformatics, ClinVar and related clinical interpretation resources connect sequence analysis with medical knowledge. They support diagnostic workflows, rare disease research, cancer genomics, carrier screening, pharmacogenomics, and the evaluation of inherited disease risk. Their value depends not only on the number of variants recorded but also on the quality, transparency, consistency, and traceability of the evidence supporting each interpretation. Reliable analysis requires integrating ClinVar with population databases, gene–disease resources, phenotype ontologies, functional annotation tools, and clinical observations. As genomic sequencing becomes more widely used, these resources will remain central to evidence-based variant interpretation, clinical reporting, and precision medicine.
Author:

Leave a Reply

Your email address will not be published. Required fields are marked *